GUMC researchers find gene function 'lost' in melanoma and gl...( Waldman says. Now we have provided th...)
Navigation Links
GUMC researchers find gene function 'lost' in melanoma and glioblastoma
Date:12/14/2008
," Waldman says. "Now we have provided the first functional evidence that PTPRD is a tumor suppressor gene, and potentially an important one at that."
'/>"/>
| Contact: Karen Mallet km463@georgetown.edu 414-312-7085 Georgetown University Medical Center Source:Eurekalert |
Related biology news :
1. Researchers identify proteins involved in new neurodegenerative syndrome
2. Texas researchers and educators head for Antarctica
3. MGH researchers describe new way to identify, evolve novel enzymes
4. University of Pennsylvania researchers develop formula to gauge risk of disease clusters
5. U of MN researchers discover noninvasive diagnostic tool for brain diseases
6. U of Minnesota researchers discover noninvasive diagnostic tool for brain diseases
7. Researchers discover new strategies for antibiotic resistance
8. Researchers find new taste in fruit flies: carbonated water
9. Binghamton University researchers investigate evolving malaria resistance
10. UIC researchers find promising new targets for antibiotics
11. Researchers develop simple method to create natural drug products
Post Your Comments:
Breaking Biology News(10 mins):Type 2 diabetes gene predisposes children to obesity 2New understanding of how to prevent destruction of a tumor suppressor 2Biogen Idec's oral compound BG-12 achieves development milestones in MS and RA 2Medifast Inc Named by Forbes as One of Americas 200 Best Small Companies 59631 1Medifast Inc Named by Forbes as One of Americas 200 Best Small Companies 59631 2Medifast Inc Named by Forbes as One of Americas 200 Best Small Companies 59631 3APIC Announces Winner of First Healthcare Administrator Award 59628 1APIC Announces Winner of First Healthcare Administrator Award 59628 2APIC Announces Winner of First Healthcare Administrator Award 59628 3Wound Management Technologies Announces Clinical Study Presentation of CellerateRx 28R 29 Technology at Leading Skin and Wound Care Conference 59625 1Wound Management Technologies Announces Clinical Study Presentation of CellerateRx 28R 29 Technology at Leading Skin and Wound Care Conference 59625 2Wound Management Technologies Announces Clinical Study Presentation of CellerateRx 28R 29 Technology at Leading Skin and Wound Care Conference 59625 3
Other Biology News:Plant studies reveal how, where seeds store iron 2New way of tracking muscle damage from radiation 2
Breaking Biology Technology:Lyric Presents the Sounds of the Season 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 2Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 3Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 4
[0] Lyric Presents the Sounds of the Season[0] Super cool atom thermometer[0] AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology[0] Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A
Other Biology Technology:Sustainable Oils Names Scott Johnson as General Manager, Expands Management Team for Camelina Research and Production 2Sustainable Oils Names Scott Johnson as General Manager, Expands Management Team for Camelina Research and Production 3Sustainable Oils Names Scott Johnson as General Manager, Expands Management Team for Camelina Research and Production 4TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel 2TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel 3TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel 4Isolagen to Host Investor Conference Call to Present an Analysis of the Data from Phase III Wrinkle Studies 2
Sustainable Oils Names Scott Johnson as General Manager, Expands Management Team for Camelina Research and ProductionTorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of TezampanelIsolagen to Host Investor Conference Call to Present an Analysis of the Data from Phase III Wrinkle Studies
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |